Rapid Nutrition PLC Announces Trading Update ahead of FY2021 Results
This release contains revenues, costs, earnings and key performance indicators (KPIs) for the year ended 31 December 2021 (FY).
London, United Kingdom – Achieving a substantial increase in the company’s bottom line compared to last year, Rapid Nutrition PLC (Euronext Growth: ALRPD, OTCQB: RPNRF), today released a trading update ahead its year-end results to be published by 30 April 2022. A natural healthcare company focused on evidenced-based nutrition, diet management and life sciences products with growing worldwide distribution, Rapid Nutrition focused on expanding operations and distribution across the globe in addition to new direct-to-consumer channels in 2021.
Financial highlights for the period include:
- Revenue for the period reached $3 million (FY 2021, 12 month period) remaining consistent with previous years comparable period (FY 2020 extended 18 month period $3.67 million)
- Gross profit increased to $2.25 million (FY2021), compared to previous extended financial period $1.5 million (FY 2020)
- Operating profit $0.439 million (FY2021), compared to previous year -$0.576 million (FY2020)
- Decrease in liabilities for the period, compared to previous year
- Substantially increased cash position (post balance sheet close, Q1 2022), positioning the company well leading into the new year and post pandemic.
“We continue make significant investments in our outstanding team, intellectual property and product innovation through our flagship brand, which has further sparked international interest in conjunction with the ongoing demand for organic, science-based health and wellness products,” said Rapid Nutrition CEO Simon St. Ledger. “In 2022, we will continue to generate growth in current markets by diversifying distribution channels while leveraging unique manufacturing capabilities and partnerships to optimize the supply chain, all with an eye towards additional growth.”
In 2021 alone, Rapid Nutrition secured distribution deals in the Middle East and South Korea in addition to notable ecommerce gains. The company successfully listed on the Euronext, Europe’s largest stock exchange, while receiving second-round investments from a group of institutional investors. Rapid Nutrition also initiated preparation to launch this year a significant oral anti-viral prevention therapy designed to help relieve cold and flu symptoms; the therapy was granted an Innovation Patent in 2016.
“Despite another year where the global pandemic significantly impacted retail, Rapid Nutrition is proud of its compelling 2021 results and we look forward to growth driven by operational execution and international expansion this year and beyond,” St. Ledger added. “We will continue to advance our work towards becoming a major player in the wellness industry and strongly believe in our company’s promise, with management invested as owners.”
About Rapid Nutrition
Dedicated to the development and distribution of premium, science-based health and wellness brands across the globe, Rapid Nutrition shares a wealth of award-winning products with consumers who are passionate about innovations that are “made by nature, refined by science.” Rapid Nutrition’s first-class scientific team matches the experience of its management team to keep both the company and consumers on top of the latest industry trends and developments, while aligning with industry leaders worldwide to deliver effective supplements and solutions. Rapid Nutrition aims to be the supplier of choice globally by offering premium brands with the highest-quality ingredients to deliver maximum results.
For more information, please visit http://rnplc.com
Investor Relations Contact:
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).